ArticleGenes & cancer2012
KRAS Testing: A Tool for the Implementation of Personalized Medicine.
Article in Genes & cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Diagnostic accuracy of high resolution melting analysis for detection of KRAS mutations: a systematic review and meta-analysis.Scientific reports · 2014Pooled it
- What Are the Practical Applications of Single-Cell Proteomics?Proteomes · 2026Article
- KRAS mutations detection methodology: from RFLP to CRISPR/Cas based methods.Functional & integrative genomics · 2024Review
- Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers.Cancers · 2023Review
- Combining the amplification refractory mutation system and high-resolution melting analysis for KRAS mutation detection in clinical samples.Analytical and bioanalytical chemistry · 2023Article
- Assessment of Tissue Adequacy by EBUS in Conjunction with PET Scan and Operator's Experience.Clinics and practice · 2022Article
- Rapid Multiplex Strip Test for the Detection of Circulating Tumor DNA Mutations for Liquid Biopsy Applications.Biosensors · 2022Article
- The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia.F1000Research · 2022Article
- Untangling the KRAS mutated lung cancer subsets and its therapeutic implications.Molecular biomedicine · 2021Review
- Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2021Review
- Optimisation of an Electrochemical DNA Sensor for Measuring KRAS G12D and G13D Point Mutations in Different Tumour Types.Biosensors · 2021Article
- Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2020Review
- RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.Molecular oncology · 2019Article
- Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer.Cancers · 2019Article
- Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC).Contemporary oncology (Poznan, Poland) · 2018Review
- Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping.Sensors (Basel, Switzerland) · 2017Article
- Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie.Journal of gastrointestinal oncology · 2017Review
- Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- RAS testing in metastatic colorectal cancer: advances in Europe.Virchows Archiv : an international journal of pathology · 2016Review
- Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients.Current pharmaceutical design · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activating point mutations in codons 12, 13, and 61 of the KRAS proto-oncogene are common in colorectal, non-small cell lung, pancreatic, and thyroid cancers. Constitutively activated KRAS mutations are strongly associated with a resistance to anti-epidermal growth factor receptor (EGFR) therapies, such as panitumumab and cetuximab used for treating metastatic colorectal carcinoma and EGFR tyrosine inhibitors used for advanced non-small cell lung cancers. Since anti-EGFR therapies are costly and may exert deleterious effects on individuals without activating mutations, KRAS mutation testing is recommended prior to the initiation of anti-EGFR therapy for these malignancies. The goal of this review is to summarize the KRAS mutation testing methods. Testing is now routinely requested in the clinical practice to provide data to assign the most appropriate anticancer chemotherapy for each given patient. Review of the most relevant literature was performed. Several areas were considered: ordering of the test, selection of the sample to be tested, and review of the testing methodologies. We found that several different methods are used for clinical KRAS mutation testing. Each of the methodologies is described, and information is provided about their performance, cost, turnaround times, detection limits, sensitivities, and specificities. We also provided "tips" for the appropriate selection and preparation of the sample to be tested. This is an important aspect of KRAS testing for clinical use, as the results of the test will affect clinical decisions with consequences for the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.